BioNexus Gene Lab Corp. (BGLC)

BioNexus Gene Lab Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	5.83	5.93	2.12	2.12	2.79	0.86
Short-Term Investments	3.34	3.31	1.51	1.55	2.09	0.49
Cash & Cash Equivalents	5.83	5.93	2.12	2.12	2.79	0.86
Cash Growth	195.57%	179.84%	-0.24%	-23.81%	224.50%	-31.83%
Receivables	0.89	0.98	2.93	3.44	4.02	0.02
Inventory	1.08	1.14	0.98	1.52	1.18	0.01
Other Current Assets	-3.24	-3.31	-1.51	-1.48	-2.09	-0.49
Total Current Assets	7.91	8.05	6.02	7.15	7.99	0.88
Property, Plant & Equipment	1.6	1.65	1.57	1.68	1.85	0.34
Long-Term Investments	1.66	1.7	1.15	0.75	0.28	0.01
Total Long-Term Assets	3.26	3.35	2.72	2.42	2.13	0.35
Total Assets	11.16	11.4	8.74	9.57	10.12	1.23
Accounts Payable	1.43	1.4	1.86	2.01	3.17	0
Deferred Revenue	0	0	0.02	0.11	0	0
Current Debt	0.03	0.03	0.02	0.04	0.05	0.03
Other Current Liabilities	0.25	0.19	0.1	0.17	0.16	0.02
Total Current Liabilities	1.72	1.63	2	2.33	3.37	0.05
Long-Term Debt	0.09	0.1	0.04	0.04	0.08	0.06
Other Long-Term Liabilities	0.01	0.01	0.03	0.03	0	0
Total Long-Term Liabilities	0.1	0.11	0.07	0.07	0.08	0.06
Total Liabilities	1.82	1.74	2.08	2.39	3.45	0.11
Total Debt	0.12	0.13	0.06	0.08	0.12	0.09
Debt Growth	131.55%	134.95%	-26.22%	-37.65%	38.00%	8.98%
Common Stock	17.19	17.19	10.93	10.78	10.78	6.48
Retained Earnings	-1.95	-1.84	1.16	1.51	0.76	-0.33
Comprehensive Income	-0.89	-0.68	-0.41	-0.1	0.13	-0.02
Shareholders' Equity	9.34	9.66	6.67	7.18	6.66	1.12
Total Liabilities and Equity	11.16	11.4	8.74	9.57	10.12	1.23
Net Cash / Debt	9.05	9.1	3.57	3.59	4.75	1.26
Net Cash / Debt Growth	159.63%	155.00%	-0.65%	-24.41%	276.37%	7.17%
Net Cash Per Share	0.51	0.57	0.25	0.25	0.55	0.18
Working Capital	6.19	6.42	4.02	4.82	4.61	0.83
Book Value Per Share	0.53	0.61	0.46	0.50	0.78	0.16

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.